These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
474 related articles for article (PubMed ID: 17216817)
41. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647 [TBL] [Abstract][Full Text] [Related]
42. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer. Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215 [TBL] [Abstract][Full Text] [Related]
43. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022 [TBL] [Abstract][Full Text] [Related]
44. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Kroman N; Holtveg H; Wohlfahrt J; Jensen MB; Mouridsen HT; Blichert-Toft M; Melbye M Cancer; 2004 Feb; 100(4):688-93. PubMed ID: 14770422 [TBL] [Abstract][Full Text] [Related]
45. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome. Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077 [TBL] [Abstract][Full Text] [Related]
46. Do very young Korean breast cancer patients have worse outcomes? Kim JK; Kwak BS; Lee JS; Hong SJ; Kim HJ; Son BH; Ahn SH Ann Surg Oncol; 2007 Dec; 14(12):3385-91. PubMed ID: 17899295 [TBL] [Abstract][Full Text] [Related]
47. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study. Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA Breast J; 2009; 15(2):120-32. PubMed ID: 19292797 [TBL] [Abstract][Full Text] [Related]
48. Pattern of metastatic spread in triple-negative breast cancer. Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA Breast Cancer Res Treat; 2009 May; 115(2):423-8. PubMed ID: 18543098 [TBL] [Abstract][Full Text] [Related]
49. Prognostic and predictive factors in early-stage breast cancer. Cianfrocca M; Goldstein LJ Oncologist; 2004; 9(6):606-16. PubMed ID: 15561805 [TBL] [Abstract][Full Text] [Related]
50. Prognostic significances of estrogen and progesterone receptors in primary operable breast cancer. Kurebayashi J; Ishida T; Higashi Y; Suemasu K; Nomoto C; Yoshida K Jpn J Clin Oncol; 1990 Sep; 20(3):271-80. PubMed ID: 2255103 [TBL] [Abstract][Full Text] [Related]
51. Pulmonary metastases of breast cancer. When is resection indicated? Welter S; Jacobs J; Krbek T; Tötsch M; Stamatis G Eur J Cardiothorac Surg; 2008 Dec; 34(6):1228-34. PubMed ID: 18824371 [TBL] [Abstract][Full Text] [Related]
52. Is triple negative a prognostic factor in breast cancer? Nishimura R; Arima N Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692 [TBL] [Abstract][Full Text] [Related]
53. [Recurrence and survival rates among early breast cancer cases with triple negative immunophenotype]. Gerson R; Alban F; Villalobos A; Serrano A Gac Med Mex; 2008; 144(1):27-34. PubMed ID: 18619055 [TBL] [Abstract][Full Text] [Related]
54. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis. Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590 [TBL] [Abstract][Full Text] [Related]
55. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091 [TBL] [Abstract][Full Text] [Related]
56. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012 [TBL] [Abstract][Full Text] [Related]
57. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. Ahn SH; Son BH; Kim SW; Kim SI; Jeong J; Ko SS; Han W; J Clin Oncol; 2007 Jun; 25(17):2360-8. PubMed ID: 17515570 [TBL] [Abstract][Full Text] [Related]
58. Prognostic impact of triple negative phenotype in conservatively treated breast cancer. Barbieri V; Sanpaolo P; Genovesi D Breast J; 2011; 17(4):377-82. PubMed ID: 21615820 [TBL] [Abstract][Full Text] [Related]
59. The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conserving therapy. Harris EE; Hwang WT; Lee EA; Cengel KA; Feldman MD; Demichele A; Kao G; Solin LJ Breast J; 2006; 12(5):431-6. PubMed ID: 16958961 [TBL] [Abstract][Full Text] [Related]
60. Patterns of surgical treatment for women with breast cancer in relation to age. Wang J; Kollias J; Boult M; Babidge W; Zorbas HN; Roder D; Maddern G Breast J; 2010; 16(1):60-5. PubMed ID: 19889171 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]